Hot Selling 99% Weight Loss CAS 282526-98-1 Cetilistat Powder

• Customization: Available
• Product Name: Cetilistat
• Other Name: New Alistat
• Model NO.: TGY2022050509
• CAS No.: 282526-98-1
• Einecs: 1308068-626-2
• Mf: C25h39no3
• Molecular Weight: 401.58
• Content: 98%
• Grade: Daily Chemical/ Food
• Brand: Tgy
• Hazardous Chemicals: No
• MOQ: 1kg
• Storage: Cool Dry Place
• Shelf Life: 2 Years
• Transport Package: Foil Bag
• Specification: powder
• Trademark: TGYBIO
• Origin: China Mainland
• HS Code: 2934991000
• Production Capacity: 500kg Per Month

Product Description

Product Name: Cetilistat

Brand Name: New alistat, Oblean,Cametor,ATL-962

CAS No.:  282526-98-1

Molecular Formula:C25H39NO3

Molecular Weight: 401.58g/mol

Purity : 99% HPLC

Solubility :Soluble in DMSO, not in water

Appearance:  White to Off-white Crystalline Powder

Typical use: Treatment of obesity and diabetes

Standard Packing : 100gram,1kg ,25kg 

Shelf Life :2 years

Storage:Room temperature away from light

Cetilistat, also known as ATL-962, it is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes. It acts in the same way as the older drug orlistat (Xenical) by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested. This medicine should be taken along with a healthy low-fat diet and an abundant amount of exercise to achieve the best possible results.

In human trials, cetilistat powder was shown to produce similar weight loss to orlistat, but also produced similar side effects such as oily, loose stools, fecal incontinence, frequent bowel movements, and flatulence. It is likely that the same precautions would apply in that absorption of fat-soluble vitamins and other fat-soluble nutrients may be inhibited, requiring vitamin supplements to be used to avoid deficiencies.

1- Treatment of obesity
2-Reduction in body weight
3-Treatment of diabetes
4-Well tolerated compared to other drugs
A novel pancreatic lipase inhibitor for the treatment of obesity in both diabetic and non-diabetic patients.
As with orlistat, cetilistat works via inhibition of pancreatic lipases in the gut to inhibit fat absorption and thereby reduce caloric uptake from diet. The medicinal chemistry program has not been described in the scientific literature, but the patent describing cetilistat also describes the synthesis of analogs with varied aryl substituents and lipophilic tails.